Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
an open, prospective, observational study to collect data on safety (major bleeding events)
and efficacy (symptomatic venous thromboembolism(VTE)) of a switch from Enoxaparin to
dabigatran etexilate in patients with total knee replacement (TKR) and total hip replacement
(THR)